ImmuCell Corporation (ICCC) Net margin 2017–2025
ImmuCell Corporation (ICCC) net profit margin by fiscal year — reported net income divided by reported revenue.
-3.8%FY2025 · since FY2017: -1.6% → -3.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -3.8% | +4.4 pp |
| FY2024 | -8.1% | +24.9 pp |
| FY2023 | -33.1% | -19.6 pp |
| FY2022 | -13.4% | -13.0 pp |
| FY2021 | -0.4% | +6.3 pp |
| FY2020 | -6.7% | +2.8 pp |
| FY2019 | -9.4% | +11.7 pp |
| FY2018 | -21.1% | -19.5 pp |
| FY2017 | -1.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice